aTyr Pharma, Inc. NASDAQ:LIFE aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Location: 3545 John Hopkins Ct Ste 250, California, 92121-1115, US | Website: www.atyrpharma.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing